Alnylam (ALNY): Leerink Swann Says Diflunisal Data De-Risks Patisiran
Tweet Send to a Friend
Leerink Swann maintained an Outperform rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a price target of $82.00. Analyst Marko Kozul ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
